Jones Hill Capital Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$466.5M
Q ending 2026-03-31
Prior quarter
–
Q ending 2025-12-31
Change
– QoQ
Positions
26
reported holdings
Largest positions
All 26 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | BMRN | Shares | $71.7M | 1.3M |
| Vertex Pharmaceuticals Inc | VRTX | Shares | $48.5M | 109K |
| Vaxcyte Inc | PCVX | Shares | $37.5M | 645K |
| Nuvalent Inc | 5AX | Shares | $30.8M | 301K |
| Capricor Therapeutics Inc | CAPR | Shares | $27.6M | 909K |
| Terns Pharmaceuticals Inc | 430 | Shares | $27.5M | 521K |
| Bicara Therapeutics Inc | BCAX | Shares | $25.1M | 1.3M |
| Ani Pharmaceuticals Inc | ANIP | Shares | $24.5M | 319K |
| Ultragenyx Pharmaceutical In | RARE | Shares | $24.4M | 1.2M |
| Enliven Therapeutics Inc | ELVN | Shares | $23.2M | 593K |
| Amylyx Pharmaceuticals Inc | AMLX | Shares | $22.2M | 1.6M |
| Argenx Se | ARGX | Shares | $19.0M | 26K |
| Fulcrum Therapeutics Inc | FULC | Shares | $13.6M | 1.8M |
| Vir Biotechnology Inc | VIR | Shares | $10.7M | 1.2M |
| Nuvation Bio Inc | NUVB | Shares | $10.2M | 2.4M |
| Oruka Therapeutics Inc | ORKA | Shares | $6.9M | 141K |
| Contineum Therapeutics Inc | CTNM | Shares | $6.7M | 513K |
| Veradermics Inc | MANE | Shares | $6.4M | 101K |
| Tonix Pharmaceuticals Hldg C | TNXP | Shares | $6.2M | 452K |
| Structure Therapeutics Inc | GPCR | Shares | $4.8M | 101K |
| Entrada Therapeutics Inc | TRDA | Shares | $4.7M | 374K |
| Pharvaris N V | Shares | $4.7M | 167K | |
| Trevi Therapeutics Inc | TRVI | Shares | $4.4M | 370K |
| Relmada Therapeutics Inc | RLMD | Shares | $2.4M | 343K |
| Silence Therapeutics Plc | SLN | Shares | $1.6M | 302K |
| Arrivent Biopharma Inc | AVBP | Shares | $1.1M | 46K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.